Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $892,125.00 in Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CFO Scott Burrows sold 12,500 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $71.37, for a total transaction of $892,125.00. Following the transaction, the chief financial officer directly owned 97,994 shares of the company’s stock, valued at approximately $6,993,831.78. This trade represents a 11.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics Stock Performance

Shares of NASDAQ:SYRE opened at $69.42 on Monday. The company has a market cap of $5.47 billion, a price-to-earnings ratio of -33.38 and a beta of 3.12. The company has a 50-day moving average price of $51.75 and a 200-day moving average price of $37.61. Spyre Therapeutics, Inc. has a 12 month low of $12.28 and a 12 month high of $76.00.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.04). As a group, research analysts forecast that Spyre Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Spyre Therapeutics

A number of institutional investors have recently made changes to their positions in SYRE. Summit Securities Group LLC purchased a new stake in shares of Spyre Therapeutics during the first quarter valued at approximately $28,000. Russell Investments Group Ltd. grew its holdings in shares of Spyre Therapeutics by 2,881.7% during the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after buying an additional 4,092 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Spyre Therapeutics during the fourth quarter valued at approximately $74,000. Tower Research Capital LLC TRC grew its holdings in shares of Spyre Therapeutics by 182.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock valued at $86,000 after buying an additional 3,725 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Spyre Therapeutics by 61.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company’s stock valued at $124,000 after buying an additional 1,435 shares during the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Key Stories Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Yahoo Finance ran a feature asking whether Spyre is one of the small-cap stocks “on fire,” highlighting recent momentum and investor interest that can support valuation and liquidity. Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
• Neutral Sentiment: Spyre’s Compensation Committee approved inducement stock options totaling 20,800 shares for four non-executive hires — a common hiring tool; dilution is small but notable if hiring accelerates. Spyre Therapeutics Announces Grants of Inducement Awards
• Negative Sentiment: CEO Cameron Turtle sold 15,000 shares at ~$71.37 under a 10b5-1 plan (≈$1.07M); although planned, large insider sales can signal executives taking profits after the run-up. SEC Form 4 — Cameron Turtle
• Negative Sentiment: Insider Sheldon Sloan sold 78,333 shares at ~$71.50 (~$5.6M), reducing his position by half via a 10b5-1 plan — a large, headline-grabbing sale that likely pressured sentiment. SEC Form 4 — Sheldon Sloan
• Negative Sentiment: CFO Scott L. Burrows sold 12,500 shares at ~$71.37 (~$892k) under a 10b5-1 plan, trimming ~11% of his holdings — another insider sale adding to downward pressure. SEC Form 4 — Scott L. Burrows

Analysts Set New Price Targets

A number of equities analysts recently issued reports on SYRE shares. Wells Fargo & Company increased their price target on shares of Spyre Therapeutics from $50.00 to $90.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 14th. Wall Street Zen downgraded shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Spyre Therapeutics from $55.00 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Leerink Partners increased their price target on shares of Spyre Therapeutics from $49.00 to $106.00 and gave the stock an “outperform” rating in a research note on Monday, April 13th. Finally, BTIG Research increased their price target on shares of Spyre Therapeutics from $70.00 to $98.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $85.08.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.